You are here: Home » Companies » News
Business Standard

Sun Pharma, Mylan face price fixing charges in US

Suit also filed against Sandoz and Mylan for colluding to hike price of another respiratory drug

Veena Mani  |  New Delhi 

Pharma

A New York grocery workers' union filed a class action suit in a Pennsylvania federal court last week against Sun Pharamceutical Industries in the US for colluding with for conspiring to raise the price of generic asthma medicine (tablets). The same union also filed another suit for similar charges against and for colluding to boost the cost of another generic asthma medicine (Benazepril HCTZ).

The complaint stated that Sun Pharmaceuticals and had raised their prices for over 3,000 per cent between October 2013 and April 2014. Business Standard has reviewed a copy of the complaint. Sun Pharma did not respond to email query sent to the company.



"Beginning in May 2013, defendants caused the price of to dramatically increase in unison," said the complaint. "The increases were the result of an agreement among defendants to increase pricing and restrain competition for the sale of in the United States," it said. The complaint detailed the meetings including meetings in Bethesda, Maryland in October 2012 and June 2013 that were attended by defendants.

The move also comes close to forty states in the US coming together to bring antitrust claims against six drug makers about three weeks back. This includes the US unit of India's along with global players Heritage, Mylan, Teva, Citron Pharma and Mayne Pharma.

Sun Pharma, Mylan face price fixing charges in US
The antitrust claims, first brought by 20 states in December, alleged that the pharmaceutical illegally conspired to divvy up the market for doxycycline hyclate (antibiotic used to treat respiratory infections), and glyburide (an oral diabetes medication) so that prices soar.

The action, led by Connecticut, stems from an investigation that state began in July 2014 into suspicious price increases of generic drugs throughout the industry. On 1 March 20 more states joined to the claims. did not respond to email query sent.

The antitrust claims against Indian have been rising in the US as late last year the US Department of Justice (DOJ) began anti-trust probe against a dozen including Indian drug makers Dr Reddy's, Sun Pharma, its US subsidiary The prices for price collusion against these related to about two dozen drugs.

RECOMMENDED FOR YOU

Sun Pharma, Mylan face price fixing charges in US

Suit also filed against Sandoz and Mylan for colluding to hike price of another respiratory drug

A class action suit has been filed against Inda-based Sun Pharmaceutical and US-based Mylan in a district court in Pennsylvania, America. Filed last week, it accuses the two companies of colluding to raise the price of albuterol sulfate tablets. Albuterol is a bronchodilator, used by patients suffering from wheezing. The suit has been filed by the United Food and Commercial Workers local unit (Local 1500); the union is the largest in New York. The suit is also against Sandoz, with the union alleging Mylan and Sandoz colluded to increase the price of Benazepril, another drug for a respiratory ailment. The allegation against Sun is that Mylan and it had raised their prices for albuterol sulfate by over 3,000 per cent between October 2013 and April 2014. Business Standard has a copy of the complaint. It reads, "Beginningin May 2013, defendants caused the price of albuterol sulfate to dramatically increase in unison. The increases were the result of an agreement among them to increase ... A New York grocery workers' union filed a class action suit in a Pennsylvania federal court last week against Sun Pharamceutical Industries in the US for colluding with for conspiring to raise the price of generic asthma medicine (tablets). The same union also filed another suit for similar charges against and for colluding to boost the cost of another generic asthma medicine (Benazepril HCTZ).

The complaint stated that Sun Pharmaceuticals and had raised their prices for over 3,000 per cent between October 2013 and April 2014. Business Standard has reviewed a copy of the complaint. Sun Pharma did not respond to email query sent to the company.

"Beginning in May 2013, defendants caused the price of to dramatically increase in unison," said the complaint. "The increases were the result of an agreement among defendants to increase pricing and restrain competition for the sale of in the United States," it said. The complaint detailed the meetings including meetings in Bethesda, Maryland in October 2012 and June 2013 that were attended by defendants.

The move also comes close to forty states in the US coming together to bring antitrust claims against six drug makers about three weeks back. This includes the US unit of India's along with global players Heritage, Mylan, Teva, Citron Pharma and Mayne Pharma.

Sun Pharma, Mylan face price fixing charges in US
The antitrust claims, first brought by 20 states in December, alleged that the pharmaceutical illegally conspired to divvy up the market for doxycycline hyclate (antibiotic used to treat respiratory infections), and glyburide (an oral diabetes medication) so that prices soar.

The action, led by Connecticut, stems from an investigation that state began in July 2014 into suspicious price increases of generic drugs throughout the industry. On 1 March 20 more states joined to the claims. did not respond to email query sent.

The antitrust claims against Indian have been rising in the US as late last year the US Department of Justice (DOJ) began anti-trust probe against a dozen including Indian drug makers Dr Reddy's, Sun Pharma, its US subsidiary The prices for price collusion against these related to about two dozen drugs.
image
Business Standard
177 22

Sun Pharma, Mylan face price fixing charges in US

Suit also filed against Sandoz and Mylan for colluding to hike price of another respiratory drug

A New York grocery workers' union filed a class action suit in a Pennsylvania federal court last week against Sun Pharamceutical Industries in the US for colluding with for conspiring to raise the price of generic asthma medicine (tablets). The same union also filed another suit for similar charges against and for colluding to boost the cost of another generic asthma medicine (Benazepril HCTZ).

The complaint stated that Sun Pharmaceuticals and had raised their prices for over 3,000 per cent between October 2013 and April 2014. Business Standard has reviewed a copy of the complaint. Sun Pharma did not respond to email query sent to the company.

"Beginning in May 2013, defendants caused the price of to dramatically increase in unison," said the complaint. "The increases were the result of an agreement among defendants to increase pricing and restrain competition for the sale of in the United States," it said. The complaint detailed the meetings including meetings in Bethesda, Maryland in October 2012 and June 2013 that were attended by defendants.

The move also comes close to forty states in the US coming together to bring antitrust claims against six drug makers about three weeks back. This includes the US unit of India's along with global players Heritage, Mylan, Teva, Citron Pharma and Mayne Pharma.

Sun Pharma, Mylan face price fixing charges in US
The antitrust claims, first brought by 20 states in December, alleged that the pharmaceutical illegally conspired to divvy up the market for doxycycline hyclate (antibiotic used to treat respiratory infections), and glyburide (an oral diabetes medication) so that prices soar.

The action, led by Connecticut, stems from an investigation that state began in July 2014 into suspicious price increases of generic drugs throughout the industry. On 1 March 20 more states joined to the claims. did not respond to email query sent.

The antitrust claims against Indian have been rising in the US as late last year the US Department of Justice (DOJ) began anti-trust probe against a dozen including Indian drug makers Dr Reddy's, Sun Pharma, its US subsidiary The prices for price collusion against these related to about two dozen drugs.

image
Business Standard
177 22